Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Nathalie Adda Sells 4,047 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Nathalie Adda sold 4,047 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, October 11th. The shares were sold at an average price of $70.34, for a total transaction of $284,665.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Nathalie Adda also recently made the following trade(s):

  • On Friday, October 8th, Nathalie Adda sold 13,453 shares of Enanta Pharmaceuticals stock. The shares were sold at an average price of $70.09, for a total value of $942,920.77.

NASDAQ:ENTA opened at $69.64 on Thursday. The company has a fifty day simple moving average of $55.88 and a two-hundred day simple moving average of $50.29. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -16.78 and a beta of 0.43. Enanta Pharmaceuticals, Inc. has a 52 week low of $40.32 and a 52 week high of $72.00.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($1.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.41) by $0.22. The business had revenue of $21.62 million during the quarter, compared to the consensus estimate of $21.87 million. Enanta Pharmaceuticals had a negative net margin of 86.21% and a negative return on equity of 14.86%. As a group, research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.15 earnings per share for the current fiscal year.

A number of analysts have issued reports on the company. Jefferies Financial Group assumed coverage on Enanta Pharmaceuticals in a research report on Wednesday, October 6th. They issued a “buy” rating and a $95.00 target price on the stock. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Monday. JMP Securities boosted their target price on Enanta Pharmaceuticals from $70.00 to $77.00 and gave the company an “outperform” rating in a research report on Friday, August 6th. Royal Bank of Canada cut their target price on Enanta Pharmaceuticals from $52.00 to $50.00 and set a “sector perform” rating on the stock in a research report on Friday, August 6th. Finally, SVB Leerink started coverage on Enanta Pharmaceuticals in a research report on Thursday, September 9th. They issued a “market perform” rating and a $55.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $68.50.

Several hedge funds have recently modified their holdings of ENTA. Northern Trust Corp grew its stake in shares of Enanta Pharmaceuticals by 171.3% during the first quarter. Northern Trust Corp now owns 644,914 shares of the biotechnology company’s stock worth $31,807,000 after purchasing an additional 407,185 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Enanta Pharmaceuticals by 21.4% during the second quarter. Armistice Capital LLC now owns 2,000,000 shares of the biotechnology company’s stock worth $88,020,000 after purchasing an additional 352,000 shares in the last quarter. Millennium Management LLC grew its stake in shares of Enanta Pharmaceuticals by 490.2% during the second quarter. Millennium Management LLC now owns 140,742 shares of the biotechnology company’s stock worth $6,194,000 after purchasing an additional 116,897 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth $5,620,000. Finally, Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 8.9% during the second quarter. Krensavage Asset Management LLC now owns 939,650 shares of the biotechnology company’s stock worth $41,354,000 after purchasing an additional 76,802 shares in the last quarter.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Featured Article: What is basic economics?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.